Urogenital Infections and Inflammations

T.E. Bjerklund Johansen, F. M.E. Wagenlehner, Y.-H. Cho, T. Matsumoto, J. N. Krieger, D. Shoskes, K. Naber

Medical treatment for urogenital tuberculosis (UGTB)

 Christian Wejse 1


1 Department of Infectious Diseases/Center for Global Health, Dept of Public Health, Aarhus University, Aarhus University Hospital, -, Denmark

Abstract

Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery.


Medical treatment

Treatment of UGTB is in general similar to treatment for pulmonary TB. Treatment according to WHO guidelines with four drugs is used: Isoniazid (INH), Rifampicin (RIF), Ethambutol (ETH) and Pyrazinamide (PYR) as displayed in Table 1 and Table 2. Standard treatment duration is two months of intensive phase with all four drugs daily, followed by 4 or 7 months of continuation phase with only two drugs (INH+RIF), in total 6–9 months. Appropriate treatment with standard antituberculous agents for six months is usually successful in eradicating active UGTB, provided that it is drug-susceptible TB [1], and this is the general recommended duration of treatment [2], [3]. The 4-month continuation phase should therefore be used in the large majority of patients, the 7-month continuation phase should be reserved only for special groups of patients, such as patients with cavitary pulmonary TB with a positive sputum culture after the initial 2-month treatment. TB is often a multiorgan disease, and in case of involvement of CNS or bone/joint, treatment should be prolonged to 12 months. This may also be useful in cases with extensive soft-tissue involvement [4]. In particular patients with major kidney involvement and ab­scess or compromised renal function may need prolonged treatment for 9–12 months. In case of concomitant HIV infection, TB treatment may also be prolonged in particular if the patient is severely immunocompromised, and HIV testing is obligatory prior to any initiation of antituberculous treatment. Some forms of anti-retroviral treatment (ART) for HIV will require modifications in the TB treatment regimen such as replacement of Rifampicin with Rifabutin. In case of concomitant HIV infection, an infectious disease specialist should be consulted for initiation of ART, and combining ART with the necessary TB treatment is a task for a specialist because of several interactions, and this is not outlined here.

 

Table 1: Treatment regimen for UGTB

Initial 2 months

Isoniazid (INH)

300 mg

Rifampicin* (RIF)

600 mg

Ethambutol (ETH)

1,200 mg

Pyrazinamide (PYR)

2,000 mg

Pyridoxine/B-combin F

20 mg per day or

50 mg every 2nd day

Four-drug combination treatment may be used if available to reduce the pill-burden;
e.g. the widely used Rimstar which contains isoniazid, rifampicin, ethambutol and pyrazinamide.

Weight (kg)

30–39

40–54

55–70

>70

Daily tablets of Rimstar

2

3

4

5

Continuation phase the following 4 months

Isoniazid

300 mg

Rifampicin*

600 mg

Pyridoxine

20 mg per day or

50 mg every 2nd day

*Rifampicin should be taken fasting, preferably half an hour before a meal.

 

Table 2: Dose-reduction according to weight (adults <50 kg)

 

Weight
30–40 kg

 Weight
40–50 kg

Isoniazid

          300 mg

          300 mg

Rifampicin

          450 mg

          450 mg

Ethambutol

          600 mg

          800 mg

Pyrazinamide

       1,000 mg

       1,500 mg

Treatment of multi-drug resistant tuberculosis

Treatment of multi-drug resistant tuberculosis (MDR-TB) defined as resistance to both RIF and INH is a particular difficult issue, requiring use of toxic and perhaps very expensive drugs. MDR-TB constitutes globally 3.9% of new TB cases and 21% of previously treated cases [5], this equals to 580,000 new cases annually and an estimated 250,000 deaths from MDR-TB [5], unfortunately only 20% of those in need of MDR-TB treatment are enrolled on an MDR-TB treatment program. It is very important that all patients undergoing TB treatment have had samples sent for TB culture prior to treatment in order to be able to do resistance testing.

ln case of multi-drug resistance, the treatment should include the use of at least five drugs assumed to be effective, preferably documented through drug susceptibility tests. Treatment of MDR-TB is very complicated and has a duration of up to two years. In case of drug resistance, an infectious disease specialist with experience in MDR-TB treatment should be consulted, as it is generally kept on few hands because of the considerable toxicity of the drugs. Briefly the main aspects of MDR-TB treatment are outlined here, as MDR-TB constitutes up to 30% of new TB cases and 70% of re-treatment cases in some countries in Eastern Europe [6]. Treatment of MDR-TB may therefore be a very common issue faced in UGTB treatment in some areas. If possible, an expert consilium should be consulted [7]. Globally, only 50% of all MDR-TB cases are successfully treated [5]. If an MDR-TB case is not successfully treated, there is a risk of progression to XDR-TB (extensively drug resistant TB) which means additional resistance to aminoglycosides and fluorquinolones. These patients are even more difficult to treat, hence expert consultations for treatment is obligatory. XDR-TB has been reported in 117 countries and an estimated 9.5% of all patients with MDR-TB have XDR-TB [5].

The main concept in treatment of MDR-TB [8] is to use an injectable agent such as amikacin, kanamycin, or capreomycin (streptomycin is usually not used because of high rates of resistance), a fluoroquinolone (levofloxacin, moxifloxacin or gatifloxacin are recommended), and at least three other agents with probable activity (ethionamide or prothionamide, cycloserine, para-aminosalicylic acid). First line agents (PYR and ETH) with retained activity should also be used. Patients with MDR-TB require a regimen with at least five effective TB medicines during the intensive phase; PYR and four core second-line TB drugs (see Table 3) – one each from Group A and Group B, and at least two from Group C [9], [10].

Table 3: Reduced kidney function (creatinin clearance <30 ml/min); dose-reduction, adults

Isoniazid

300 mg x 1 daily (150 mg if clearance <10 ml/min and ÷ dialysis)

Rifampicin

600 mg x 1 daily

Ethambutol

15–25 mg/kg x 3 per week (avoid if no dialysis)

Pyrazinamide

1,500 mg/(25–30 mg/kg) x 3 per week

In case of haemodialysis: Antituberculous treatment should be given AFTER dialysis

Ideally the injectable agent is administered daily for the first 6–8 months, forming an “intensive phase” of treatment, with the other drugs then continued, forming a “continuation phase” which should last an additional 12–16 months. There is a short course treatment recommended for selected cases, but since extra-pulmonary TB patients are never considered for this, it does not apply to UGTB patients [10]. Very often, adverse effects (nephro- and ototoxicity) will require ceasing treatment with the injectable agent, but it is often possible to manage side effects through dose reduction to 3 times weekly or swapping drugs for remaining alternatives.

In patients with MDR-TB, surgery may also be used as a means to reduce the amount of lung tissue with intractable pathology, to reduce bacterial load and thus improve prognosis [11]. WHO now recommends elective partial lung resection (lobectomy or wedge resection) alongside a recommended MDR-TB regimen [10].

Treatment variations according to species

UGTB is usually caused by Mycobacterium tuberculosis or (in particular in West Africa) by Mycobacterium af­ri­canum. However, Mycobacterium bovis is also part of the Mycobacterium tuberculosis complex and may be seen in UGTB, in particular among elderly patients. Non-tuberculous mycobacteria are rare causes of urinary tract disease, and are not considered here. M. bovis is inherently resistant to PYR. This should therefore be avoided in such cases, and could be replaced with a flouorquinolone.

Renal impairment

In case of renal insufficiency, drug dose adjustments are required for ETH and PYR as these drugs are cleared in the kidneys, INH and RIF can safely be used without dosing adjustments, even in end-stage renal disease. Dose-adjustments are made according to Glomerular Filtration Rate (GFR), as shown in Table 4. For these particular cases, monitoring plasma drug-concentrations is useful if available. PYR may induce hyperuricaemia and hyperuricuria (which may also be used to monitor treatment adherence) but could therefore be harmful in case of urinary tract damages. In such cases, a xanthine oxydase inhibitor (Allopurinol) could be added [12].

Table 4: Drugs used for treatment of multi-drug resistant tuberculosis (MDR-TB)

 

Name of drug

Abbreviation

A. Fluoroquinolones

Levofloxacin

Moxifloxacin

Gatifloxacin

Lfx

Mfx

Gfx

B. Second-line injectable agents

Amikacin

Capreomycin

Kanamycin

(Streptomycin)

Am

Cm

Km

(S)

C. Other core second-line agents

Ethionamide/Prothionamide

Cycloserine/Terizidone

Linezolid

Clofazimine

Eto/Pto

Cs/Trd

Lzd

Cfz

D. Add-on agents

(not part of the core MDR-TB regimen)

D1

Pyrazinamide

Ethambutol

High-dose isoniazid

Z

E

Hh

 

D2

Bedaquiline

Delamanid

Bdq

Dlm

D3

p-aminosalicylic acid

Imipenem-cilastatin

Meropenem

Amoxicillin-clavulanate

(Thioacetazone)

PAS

Ipm

Mpm

Amx-Clv

T

Treatment response

The clinical response to antituberculous treatment is usually excellent because of high urinary concentrations of antituberculous drugs and good renal vascular supply. Sterilization of mycobacteria in urine usually occurs within two weeks after treatment start. Yet, there is often a considerable mortality, just as in TB disease in other organs. This is mostly because of late presentation or co-morbidity, and the overall TB mortality in 2015 was 14.5% [5]. In a UGTB cohort from Thailand the mortality was 26%, with age, comorbidity and no treatment being the major risk factors [13]. In other cohorts, mortality as low as 1% has been reported [14]. Relapse of TB is rare in culture-confirmed urinary tract disease treated with standard therapy [15], even among patients who require nephrectomy [16]. There are also some reports of high relapse rates, up to 20% in Turkey [17], [18], but historical cohorts with long follow-up >10 years indicate that cure rates of close to 100% are generally to be expected on current treatment regimens [19].

Complications during treatment

During antituberculous therapy upper urinary tract obstruction (UTO) may occur [20]. Signs and symptoms of UTO should be monitored (flank pain, renal colic, hydro­nephrosis) in order to detect this debilitating condition, which may occur in the first few weeks of antituberculous therapy. It may be interpreted as a form of paradoxical reaction to treatment, which is often seen in TB, in par­ticular but not only among HIV-infected in combination with initiating antiretroviral therapy [2], [21]. It is caused by inflammation, followed by fibrosis and obstruction of the collecting system [16]. Ureteral strictures may be caused by the disease process prior to treatment, but may also progress during treatment due to scarring and subsequent narrowing of the lumen [3]. Usually, this is occurring within the first two months of treatment [22]. Fibrosis of the bladder wall with reduced capacity is seen in 9% of patients [16]. In severe and neglected cases, bladder contractions may even develop [23].

Treatment of complications

The treatment for obstruction and other manifestations of paradoxical reaction may primarily be surgical and contractions may need major surgical reconstruction [23]. Some reports indicate a very frequent need for surgery, up to 32% of male cases with UGTB in a large India cohort [4]. When urinary tract obstructions occur, anti-tuberculous treatment is not always sufficient, and reconstructive surgery may be indicated [3]. When UGTB has led to major kidney lesions such as caverns, surgical intervention is indicated in advanced cases [24]. All surgical interventions should be performed under the coverage of anti-TB therapy. Adding corticosteroid treatment may be considered in particular in minor strictures, e.g. prednisolon 50 mg daily with gradual rundown over weeks. Supplementary treatment with corticosteroids is not generally recommended in UGTB [2], but there is no reason to fear adding corticosteroids, once the patient is on effective treatment. This will not put the patient at increased risk of disseminated disease and corticosteroid as adjunctive therapy is increasingly used even in pulmonary TB [25].

Note

This chapter was primarily published in the journal GMS Infectious Diseases [26].


References

[1] Gow JG, Barbosa S. Genitourinary tuberculosis. A study of 1117 cases over a period of 34 years. Br J Urol. 1984 Oct;56(5):449-55.
[2] Cek M, Lenk S, Naber KG, Bishop MC, Johansen TE, Botto H, Grabe M, Lobel B, Redorta JP, Tenke P; Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Office. EAU guidelines for the management of genitourinary tuberculosis. Eur Urol. 2005 Sep;48(3):353-62. DOI: 10.1016/j.eururo.2005.03.008
[3] Kulchavenya E, Naber K, Bjerklund Johansen TE. Urogenital Tuberculosis: Classification, Diagnosis, and Treatment. Eur Urol Suppl. 2016 Jul;15(4):112–21. DOI: 10.1016/j.eursup.2016.04.001
[4] Chandra S, Chandra H, Chauhan N, Gaur DS, Gupta H, Pathak VP, Burathoki SK. Male genitourinary tuberculosis – 13 years experience at a tertiary care center in India. Southeast Asian J Trop Med Public Health. 2012 Mar;43(2):364-9.
[5] World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Available from: http://www.who.int/tb/publications/global_report/en/
[6] European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2017. Stockholm: European Centre for Disease Prevention and Control; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/ecdc-tuberculosis-surveillance-monitoring-Europe-2017-WEB.pdf
[7] D’Ambrosio L, Tadolini M, Dupasquier S, Tiberi S, Centis R, Dara M, Blasi F, Migliori GB. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. Eur Respir J. 2014 Jan;43(1):286-9. DOI: 10.1183/09031936.00125813
[8] Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. BMJ. 2015 Feb;350:h882.
[9] World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014. Available from: http://www.who.int/tb/publications/pmdt_companionhandbook/en/
[10] World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis; 2016 update; October 2016 revision. Geneva: World Health Organization; 2016. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/
[11] Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis. 2016 Apr;62(7):887-95. DOI: 10.1093/cid/ciw002
[12] Naftalin CM, Verma R, Gurumurthy M, Lu Q, Zimmerman M, Yeo BCM, Tan KH, Lin W, Yu B, Dartois V, Paton NI. Coadministration of allopurinol to increase antimycobacterial efficacy of pyrazinamide as evaluated in a whole-blood bactericidal activity model. Antimicrob Agents Chemother. 2017 Oct;61(10):e00482-17. DOI: 10.1128/AAC.00482-17
[13] Hsu HL, Lai CC, Yu MC, Yu FL, Lee JC, Chou CH, Tan CK, Yang PC, Hsueh PR. Clinical and microbiological characteristics of urine culture-confirmed genitourinary tuberculosis at medical centers in Taiwan from 1995 to 2007. Eur J Clin Microbiol Infect Dis. 2011 Mar;30(3):319-26. DOI: 10.1007/s10096-010-1083-z
[14] Altiparmak MR, Trabulus S, Balkan II, Yalin SF, Denizli N, Aslan G, Doruk HE, Engin A, Tekin R, Birengel S, Cetin BD, Arslan F, Turhan V, Mert A. Urinary tuberculosis: a cohort of 79 adult cases. Ren Fail. 2015 Aug;37(7):1157-63. DOI: 10.3109/0886022X.2015.1057460
[15] Weir MR, Thornton GF. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. Am J Med. 1985 Oct;79(4):467-78. DOI: 10.1016/0002-9343(85)90034-8
[16] Figueiredo AA, Lucon AM. Urogenital tuberculosis: update and review of 8961 cases from the world literature. Rev Urol. 2008;10(3):207-17.
[17] Gokalp A, Gultekin EY, Ozdamar S. Genito-urinary tuberculosis: a review of 83 cases. Br J Clin Pract. 1990 Dec;44(12):599-600.
[18] Gokce G, Kilicarslan H, Ayan S, Tas F, Akar R, Kaya K, Gultekin EY. Genitourinary tuberculosis: a review of 174 cases. Scand J Infect Dis. 2002;34(5):338-40.
[19] Gow JG. Results of treatment in a large series of cases of genito-urinary tuberculosis and the changing pattern of the disease. Br J Urol. 1970 Dec;42(6):647-55.
[20] Psihramis KE, Donahoe PK. Primary Genitourinary Tuberculosis: Rapid Progression and Tissue Destruction During Treatment. J Urol. 1986 May;135(5):1033-6. DOI: 10.1016/S0022-5347(17)45970-2
[21] Bell LC, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. Int J Infect Dis. 2015 Mar;32:39-45. DOI: 10.1016/j.ijid.2014.12.030
[22] Shin KY, Park HJ, Lee JJ, Park HY, Woo YN, Lee TY. Role of early endourologic management of tuberculous ureteral strictures. J Endourol. 2002 Dec;16(10):755-8. DOI: 10.1089/08927790260472917
[23] Singh V, Sinha RJ, Sankhwar SN, Sinha SM. Reconstructive surgery for tuberculous contracted bladder: experience of a center in northern India. Int Urol Nephrol. 2011 Jun;43(2):423-30. DOI: 10.1007/s11255-010-9815-7
[24] Kulchavenya E. Current Therapy and Surgery for Urogenital Tuberculosis. Switzerland: Springer International Publishing; 2016.
[25] Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database Syst Rev. 2014 Nov 12;(11):CD011370. DOI: 10.1002/14651858.CD011370
[26] Wejse C. Medical treatment for urogenital tuberculosis (UGTB). GMS Infect Dis. 2018;6:Doc04. DOI: 10.3205/id000039

The ZB MED – Information Center for Life Sciences, Germany, together with the European Association of Urology (EAU) provided the opportunity to publish a “Living Textbook” on “Urogenital Infections and Inflammations” in an open access form. This “Living Textbook” represents also an update of the Textbook on Urogenital Infections published 2010 by the International Consultation on Urological Infections and the EAU: http://www.icud.info/urogenitalinfections.html.

The “Living Textbook” will cover infections and inflammations of the kidney, the urinary tract, as well as the male and female genital tract considering pathogenesis, diagnostics, treatment, prophylaxis and future aspects. The “Living Textbook” will be structured into about 26 Sections each with two section co-chairs responsible for peer review of the chapters of each section. Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

The editors hope that this “Living Textbook” may become a useful instrument for physicians of different specialties taking care about patients suffering from these diseases.

Truls E. Bjerklund Johansen (Norway),

Florian ME Wagenlehner (Germany),

Yong-Hyun Cho (South Korea),

Tetsuro Matsumoto (Japan),

John N Krieger (USA),

Daniel Shoskes (USA),

Kurt G. Naber (Germany).

Publishing at PUBLISSO

Your chapter will be published at the PUBLISSO platform (https://books.publisso.de).

Information for corresponding authors

It is necessary for all corresponding authors to register at PUBLISSO.
To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

After registration, please complete your user profile. Information from your user profile will appear in the published chapter and the authors board of the book (http://books.publisso.de/publisso_gold/book/52). If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.
(If you do not want to be displayed in the authors board, but stay registered, you can disable this feature in your profile settings. In this case, your affiliation (publication data) will be displayed in the published chapter only.)

We kindly ask you to provide the co-authors email addresses in the manuscript so that we can contact them in case of queries.

Information for co-authors

After publication of your chapter, your affiliation (publication data) will be displayed in the published chapter.

If you also want to be displayed in the authors board of the book (http://books.publisso.de/publisso_gold/book/52), we kindly ask you to register at PUBLISSO. If you are displayed in the authors board, you can be contacted by readers and other professionals. You can also contact other authors of the book for exchange and to build a network.

To register at PUBLISSO please click the following link: http://books.publisso.de/publisso_gold/register

If you do not want to be displayed in the authors board of the book, you do not have to register. Your affiliation (publication data) will be displayed in the published chapter only.

Support

If you have any further questions please don’t hesitate to contact the PUBLISSO editorial office:

E-Mail: livingbooks@zbmed.de
Phone: +49 221 478-7093

General

The textbook will be structured in sections with two co-chairs each. Each section will start with an introductory chapter written by the two respective co-chairs presented like an editorial commentary in regard to the following chapters (see proposed contents of the book). The two co-chairs of each section will also peer review all chapters in their section and stimulate a consensus discussion within their section together with the authors and the main editors if needed.

Chapters

Each chapter should reflect the background to the topic and highlight all of the critical evidence relating to the subject. The intention is to provide an up to date, concise synthesis of the literature on that topic, and for clinical topics also recommendations based on levels of evidence for contemporary clinical practice, as well as suggested research recommendations.

Manuscript

Each manuscript should have up to approximately 3,000 words (excluding abstract, tables/figures and references). The abstract should count about 300 words.

Structure

The outline of each chapter should be structured as follows (similar as in the edition 2010, which can be downloaded for free: http://www.icud.info/urogenitalinfections.html):

  1. Abstract
  2. Summary of recommendations*/key notes*
    (*which ever term is more appropriate)
  3. Introduction
  4. Methods
  5. Results
  6. Further research
  7. Conclusions
  8. Acknowledgement
  9. Conflict of interest of each author
  10. References

Citation style

As a citation style, the Vancouver style is preferred.

Please mark your references in the text with square brackets ([1], [2], ...).

Summary of recommendations

We would like to have the Summary of recommendations at the beginning after the abstract (as in the edition 2010). However, we do not expect as in the edition 2010, that each recommendation is also specified according to Level of Evidence and Grade of Recommendation, because such a claim would not only need a systematic literature search (see below), but also a structured discussion in a defined group of experts.

Systematic literature search

A systematic literature search should be performed, at least of PUBMED/MEDLINE but ideally of several relevant databases in addition (like Cochrane CENTRAL) to find recent, high quality systematic reviews and/or primary research studies. It is not expected to perform for all chapters a de novo systematic review, if such reviews are already published recently, but it still may be indicated for some items. For questions relating therapy, it should be focused on evidence from (systematic reviews of) randomized controlled trials if available.

The method of the systematic literature search needs to be fully described in the section “Methods”, e.g.:

“A systematic literature search was performed for the last ... (usually 10) years in MEDLINE, Cochrane etc. with the following key words ... and the following limitations: e.g. UTI, age (adult?), ... clinical studies ... English ... abstract available ... only peer reviewed ...

A total of ... publications were identified, which were screened by title and abstract ... After exclusion of duplicates ... a total of ... were included into the review (analysis), supplemented by citations or known to the authors ... ”.

Clinical topics

Clinical topics should be focused on the importance to clinical practice according to the up to date scientific knowledge as presented in the literature. It should relate to questions/complaints/symptoms of patient/population concerning definition, diagnosis, therapy/prevention, intervention, and outcome in comparison, if different approaches are feasible. Please choose patient-important outcomes and focus on those, which you deem critical for decision-making.

Level of evidence and grade of recommendations

Any recommendation should be based on the level of evidence and the grade of recommendation. For this purpose the following system, modified from the Oxford Centre for Evidence-based Medicine should be used (EAU guidelines 2015):

Level of evidence (LE)

Level Type of evidence
1a Evidence obtained from meta-analysis of randomised trials
1b Evidence obtained from at least one randomised trial
2a Evidence obtained from one well-designed controlled study without randomization
2b Evidence obtained from at least one other type of well-designed quasi-experimental study
3 Evidence obtained from well-designed non-experimental studies, such as comparative studies, correlation studies and case reports.
4 Evidence obtained from expert committee reports or opinions or clinical experience of respected authorities.

Grade of Recommendations (GoR)

Grade Nature of recommendations
A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial
B Based on well-conducted clinical studies, but without randomised clinical trials
C Made despite the absence of directly applicable clinical studies of good quality

Comments (EAU guidelines 2015)

The aim of assigning a LE and grading recommendations is to provide transparency between the underlying evidence and the recommendation given.

It should be noted that when recommendations are graded, the link between the level of evidence and grade of recommendation is not directly linear. Availability of randomized controlled trials may not necessarily translate into a grade “A” recommendation where there are methodological limitations or disparity in published results.

Alternatively, absence of high level evidence does not necessarily preclude a grade A recommendation, if there is overwhelming clinical experience and consensus. In addition, there may be exceptional situations where corroborating studies cannot be performed, perhaps for ethical or other reasons and in this case unequivocal recommendations are considered helpful for the reader. The quality of the underlying scientific evidence - although a very important factor – has to be balanced against benefits and burdens, values and preferences and costs when a grade is assigned.

Since the same rating system should be used in all chapters, for the sake of brevity the same sentence could be used in “Methods” for all manuscripts, because the rating system will be described in details in the Preface of the book:

“The studies were rated according to the level of evidence and the strength of recommendations graded according to a system used in the EAU guidelines modified from the Oxford Centre for Evidence-based Medicine [1].”

References

[1] European Association of Urology. Guidelines. Methodology section. 2015 ed. Arnhem: European Association of Urology; 2015. p. 3. ISBN/EAN: 978-90-79754-80-9. Available from: http://uroweb.org/wp-content/uploads/EAU-Extended-Guidelines-2015-Edn..pdf

The Living Handbook of Urogenital Infections and Inflammations is issued by:

European Association of Urology
att. Maurice Schlief, EAU executive manager business affairs

P.O.Box 30016
NL-6803 AA Arnhem, The Netherlands

Phone: 0031-26-38.90.680
E-mail: m.schlief@uroweb.org

Editor in Chief

responsible for the contents according to § 5 TMG and § 55 Abs. 2 RStV (Germany):

Kurt G. Naber, MD, PhD
Assoc. Professor of Urology

Technical University of Munich
Karl-Bickleder-Str. 44c
94315 Straubing, Germany

E-mail: kurt.naber@nabers.de

John N. Krieger MD, PhD

University of Washington Section of Urology

more

Daniel Shoskes MD, PhD

Cleveland Clinic Glickman Urological and Kidney Institute

more

Yong-Hyun Cho MD, PhD

St. Mary's Hospital, The Catholic University of Korea Department of Urology

more

Tetsuro Matsumoto MD, PhD

University of Occupational and Environmental Health Department of Urology

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen Clinic of Urology and Andrology

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital Urology Department

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Punit Bansal MD, PhD

R G Stone and Super Specialty Hospital
Department of Urology

more

Riccardo Bartoletti

University of Pisa
Department of Translational Research and New Technologies

more

Truls Erik Bjerklund Johansen MD, PhD

Oslo University Hospital
Urology Department

more

PD Dr. med. Gernot Bonkat

University Basel
alta uro AG, Merian Iselin Klinik, Center of Biomechanics & Calorimetry (COB)

more

Prof. Tommaso Cai MD

Santa Chiara Regional Hospital
Dept. of Urology

more

Dr Leyland Chuang

Ng Teng Fong Hospital, National University Health System
Department of Medicine

more

Prof. Milan Cizman

University Medical Centre
Department of Infectious Diseases

more

Alison Crawford MSc

Queen's University
Department of Psychology

more

Pfofessor Svetlana Dubrovina MD, PhD

Rostov Medical State University
Obstetrics and Gynaecology

more

Dr Valerie Huei Li Gan MBBS (S'pore), MRCS (Edin), MMed (Surg), FAMS (Urology)

Singapore General Hospital
Department of Urology

more

Philip Hanno

University of Pennsylvania

more

Ass prof MD Gundela Holmdahl

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Udo B. Hoyme

HELIOS Hospital Erfurt Ltd.
Department of Gynecology and Obstetrics

more

David Hunstad

Washington University School of Medicine
Pediatrics / Molecular Microbiology

more

Gitte M. Hvistendahl

Aarhus University Hospital

more

Prof. Michael KOGAN M.D., PhD

Rostov State Medical University
Department of Urology

more

Dr Akihiro Kanematsu

Hyogo College of Medicine
Department of Urology

more

Frieder Keller

University Hospital Ulm
Department Internal Medicine 1, Nephrology

more

Professor Katarzyna Kilis-Pstrusinska PhD, MD

Wroclaw Medical University
Department of Pediatric Nephrology

more

MD, PhD Tae-Hyoung Kim

Chung-Ang University
Urology

more

John N. Krieger MD, PhD

University of Washington
Section of Urology

more

Prof Ekaterina Kulchavenya

Novosibirsk Research TB Institute, Novosibirsk State Medical University

more

Dr Christina Kåbjörn Gustafsson

Ryhov Hospital Jönköping
Pathology

more

Dr. Bela Köves

South Pest Teaching Hospital
Department of Urology

more

Iara Linhares

Dr. med. Giuseppe Magistro

Ludwig-Maximilians-University of Munich
Department of Urology

more

Vittorio Magri

ASST-North
Urologic Clinic

more

András Magyar

South-Pest Hospital
Department of Urology

more

Professor Emeritus Brian Morris

University of Sydney
School of Medical Sciences

more

Baerbel Muendner-Hensen

ICA-Deutschland e.V.

more

Stephen F. Murphy

Feinberg School of Medicine, Northwestern University
Department of Urology

more

Kurt G. Naber MD, PhD

Technical University of Munich

more

Prof. Yulia Naboka

Rostov State Medical University
Department of Microbiology

more

Dr. J. Curtis Nickel MD

Queen's University
Department of Urology

more

Professor Ralph Peeker MD PhD

University of Gothenburg
Department of Urology

more

Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology

more

Prof. Gianpaolo Perletti M. Clin. Pharmacol.

University of Insubria
Department of Biotechnology and Life Sciences

more

Felice Petraglia

Department of Biomedical, Experimental and Clinical Sciences, University of Florence
Obstetrics and Gynecology

more

Michel Pontari

Temple University School of Medicine
Department of Urology

more

Dr. Jörgen Quaghebeur PhD. Med. Sci.

University Hospital Antwerp and University Antwerp
Department of Urology

more

Yazan F. Rawashdeh

Aarhus University Hospital
Paediatric Urology Section, Department of Urology

more

Professor Claus Riedl MD

-
Urology

more

Matthew Roberts

The University of Queensland
Faculty of Medicine

more

PD Dr. med Guido Schmiemann MPH

Institut für Public Health und Pflegeforschung, Universität Bremen
Abteilung Versorgungsforschung

more

Caroline Schneeberger MD PhD

Academic Medical Center (AMC)

more

Prof. Dr. med. Peter Schneede

Klinikum Memmingen
Department of Urology

more

Aaron C. Shoskes

Des Moines University Medical College of Ostheopathic Medicine

more

Daniel Shoskes MD, PhD

Cleveland Clinic
Glickman Urological and Kidney Institute

more

Prof. Dr. Roswitha Siener

University of Bonn
University Stone Centre, Department of Urology

more

Sofia Sjöström

Queen Silvia Childrens Hospital, Sahlgrens Academy
Pediatric surgery and urology

more

Mathew Sorensen

University of Washington School of Medicine
Department of Urology

more

Prof. Dr. Dr. Walter Ludwig Strohmaier FEBU

Regiomed-Klinikum Coburg. Medical School Regiomed
Urology and Paediatric Urology

more

Satoshi Takahashi

Sapporo Medical University School of Medicine
Department of Infection Control and Laboratory Medicine

more

Professor Paul Anantharajah Tambyah

Yong Loo Lin School of Medicine, National University Hospital
Department of Medicine

more

Peter Tenke

Jahn Ferenc South Pest Teaching Hospital
Department of Urology

more

Praveen Thumbikat


Department of Urology

more

Dr. Jose Tiran Saucedo

IMIGO / Universidad de Monterrey
Obstetrics and Gynaecology

more

Dominic Tran-Nguyen

Des Moines University

more

Dean Tripp

Queen's University
Psychology, Anesthesia & Urology

more

Prof. SEONGHEON WIE

The Catholic University of Korea, St. Vincent's Hospital
Division of Infectious Diseases, Department of Internal Medicine

more

Florian M. E. Wagenlehner MD, PhD

Justus-Liebig University of Giessen
Clinic of Urology and Andrology

more

Assoc. Prof. Christian Wejse

Aarhus University, Aarhus University Hospital
Department of Infectious Diseases/Center for Global Health, Dept of Public Health

more

Prof. Dr. Mete Çek

Trakya University, School of Medicine
Urology

more